Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2005

View Archived Issues

Efficacy of ambroxol in chronic pain models: Nav1.8 Na+ channels as targets for analgesia

Preclinical and clinical evaluation of a new potent and selective PDGFR inhibitor

Celera Genomics target HDACs for cancer therapy

Clusterin-targeted AS-ODN therapy: preclinical and clinical efficacy reported

SGN-40 begins phase I/II study for CLL

Roche obtains license to BCX-4208 in transplantation and autoimmune diseases

Three phase II cancer studies begin for ZK-EPO in Europe

Therapeutic cancer vaccine programs advance at Transgene

Tibotec discontinues study of TMC-125 in protease inhibitor-naive patients

Dosing begins in phase I study of NTx-265 for stroke

Veronate makes regulatory advances

OPi launches Erwinase in U.K.

Avelox approved for complicated intraabdominal infections in adults

Oral PDE5 inhibitor SLx-2101 begins phase IIa trial for erectile dysfunction

Treatment completed in phase I study of SB-509 in diabetic neuropathy

Higher doses of phenserine may be efficacious in mild to moderate Alzheimer's disease

AzaSite is effective against bacterial conjunctivitis using reduced dosing frequency

Humax-CD20 produces encouraging response rates in relapsed NHL patients

An oral nanoparticle formulation of taurine targeted for Alzheimer's

GSK's new VEGFR TK inhibitor for cancer

Natural antidiabetic agent as a potential therapy for AD

Shire submits MAA for idursulfase for Hunter's syndrome

EVOLVE evaluates MCC-135 as adjunct to primary PCI in patients with acute myocardial infarction

Preclinical and clinical data on sorafenib expands

Studies detail activity, pharmacokinetics and pharmacodynamics of sunitinib

Recent patents disclose therapeutic agents for gastrointestinal disorders

Novel therapeutics for neurological disorders reported in recent patent literature

Recent GSK patent imparts novel agents for respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...